La farmacéutica alemana Merck se anotó un beneficio neto atribuido de 2.777 millones de euros en 2024, lo que equivale a una ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

Las acciones de Merck&Co cotizan y se negocian en la bolsa de valores Nueva York. ¿Cuál es el símbolo bursátil de Merck&Co? El símbolo bursátil de Merck&Co es “MRK”. ¿Paga Merck&Co ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $115.00. The company’s shares closed ...

Merck, compañía líder en ciencia y tecnología, ha registrado en 2024 un aumento del volumen de negocio del 2%, hasta los 21.200 millones de euros. El ebitda (el beneficio antes de intereses ...

Estimación del precio real de una acción basada en modelos de valoración como el flujo de caja descontado, los múltiplos de valoración por pares y los modelos de descuento de dividendos.

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...